Microbiocenosis of adenocarcinoma tissue in colon cancer patients with different preoperative preparation

Purpose of the study. To assess the effect of inclusion of lactoglobulin in complex preoperative preparation of colon cancer patients on their tumor and resection line tissue microbiota.

Materials and methods. 40 patients with colon cancer stages II–III, in whom the operation was the first stage of treatment, during standard preoperative preparation, were injected with a preparation of antibodies against opportunistic intestinal microorganisms obtained from colostrum of immunized cows, 2 g twice a day orally before surgery for 3 days (total dose of 12 g) (main group); 40 patients received standard antibiotic prophylaxis (control group). The quantitative composition of the microbiota was determined in the samples of the removed tumor and tissue of the resection line.

Results. The total microbial contamination of the tumor was 9.2 times lower in the main group relative to the control group; the frequency of E.coli and Clostridiae excretion was also statistically significantly lower (p = 0.004 and 0.03, respectively). In the tumors of patients of the main group out of twelve studied representatives of microorganisms, the number of six was statistically significantly lower than in control group, and three of those found in the control group were not detected. Since they were potentially pathogenic (Pseudomonas aeruginosa, Staphylococcus aureus, fungi of the Candida spp.), the microbial composition of the tumor of patients in the main group can be considered more favorable than the control group. Similar differences were noted in non-t umor intestinal tissue, in which the content of Enterobacter spp, Streptococcus, Clostridiae, Peptostreptococci was statistically significantly lower than in the control group.

Conclusion. Thus oral administration of colostrum antibodies caused positive changes in tumor and colon tissue microbiota. We suggest the application of lactoglobulin to be useful for surgical treatment of such patients taking into account the possible impact of microbiota in patients’ response to chemo- and immunotherapy.

1.

2. Abreu MT, Peek RM. Gastrointestinal malignancy and the microbiome. Gastroenterology. 2014 May;146(6):1534-1546.e3. https://doi.org/10.1053/j.gastro.2014.01.001

3. Bagirova NS, Petukhova IN, Dmitrieva NV, Grigorievskaya ZV. Microbiome and cancer: is there a connection? Literature review. Malignant Tumours. 2018;3s1:56–69. (In Russ.). https://doi.org/10.18027/2224-5057-2018-8-3s1-56-69

4. Meng C, Bai C, Brown TD, Hood LE, Tian Q. Human Gut Microbiota and Gastrointestinal Cancer. Genomics Proteomics Bioinformatics. 2018 Feb;16(1):33–49. https://doi.org/10.1016/j.gpb.2017.06.002

5. Xu X, Ying J. Gut Microbiota and Immunotherapy. Front. Microbiol. 2022 July 1;13:945887. https://doi.org/10.3389/fmicb.2022.945887

6. Lehouritis P, Cummins J, Stanton M, Murphy CT, McCarthy FO, Reid G, et al. Local bacteria affect the efficacy of chemotherapeutic drugs. Sci Rep. 2015 Sep 29;5:14554. https://doi.org/10.1038/srep14554

7. Leslie M. Microbiome. Microbes aid cancer drugs. Science. 2015 Nov 6;350(6261):614-615. https://doi.org/10.1126/science.350.6261.614

8. Ambalam P, Raman M, Purama RK, Doble M. Probiotics, prebiotics and colorectal cancer prevention. Best Pract Res Clin Gastroenterol. 2016 Feb;30(1):119–131. https://doi.org/10.1016/j.bpg.2016.02.009

9. Zhao H, Wang D, Zhang Z, Xian J, Bai X. Effect of Gut Microbiota-Derived Metabolites on Immune Checkpoint Inhibitor Therapy: Enemy or Friend? Molecules. 2022 Jul 27;27(15):4799. https://doi.org/org/10.3390/molecules27154799

10. Kharchenko EP, Solov'ev IA. Microbiota, immune system and colorectal cancer. Pelvic Surgery and Oncology. 2017;7:11-19. (In Russ.). https://doi.org/10.17650/2220-3478-2017-7-4-11-19

11. Bartolini I, Risaliti M, Ringressi MN, Melli F, Nannini G, Amedei A, et al. Role of gut microbiota-immunity axis in patients undergoing surgery for colorectal cancer: Focus on short and long-term outcomes. World J Gastroenterol. 2020 May 28;26(20):2498–2513. https://doi.org/10.3748/wjg.v26.i20.2498

12. Mima K, Nishihara R, Qian ZR, Cao Y, Sukawa Y, Nowak JA, et al. Fusobacterium nucleatum in colorectal carcinoma tissue and patient prognosis. Gut. 2016 Dec;65(12):1973–1980. https://doi.org/10.1136/gutjnl-2015-310101

13. Repass J, Maherali N, Owen K, Reproducibility Project: Cancer Biology, Reproducibility Project Cancer Biology. Registered report: Fusobacterium nucleatum infection is prevalent in human colorectal carcinoma. Elife. 2016 Feb 11;5:e10012. https://doi.org/10.7554/eLife.10012

14. Pandey KR, Naik SR, Vakil BV. Probiotics, prebiotics and synbiotics- a review. J Food Sci Technol. 2015 Dec;52(12):7577–7587. https://doi.org/10.1007/s13197-015-1921-1

15. Aleshukina AV, Vachaev BF, Yurieva IL, Yaitsky AN. Immunomodulatory effect of low molecular weight peptides of cow colostrum. Allergology and Immunology. 2009;2(10):301. (In Russ.).

16. Chiang MK, Hsiao PY, Liu YY, Tang HL, Chiou CS, Lu MC, et al. Two ST11 Klebsiella pneumoniae strains exacerbate colorectal tumorigenesis in a colitis-associated mouse model. Gut Microbes. 2021;13(1):1980348. https://doi.org/10.1080/19490976.2021.1980348

17. Pe´richon B, Lichtl-Häfele J, Bergsten E, Delage V, Trieu-Cuot P, Sansonetti P, et al. Detection of Streptococcus gallolyticus and Four Other CRC-Associated Bacteria in Patient Stools Reveals a Potential “Driver” Role for Enterotoxigenic Bacteroides fragilis. Front Cell Infect Microbiol. 2022;12:794391. https://doi.org/10.3389/fcimb.2022.794391

18. Long X, Wong CC, Tong L, Chu ESH, Ho Szeto C, Go MYY, et al. Peptostreptococcus anaerobius promotes colorectal carcinogenesis and modulates tumour immunity. Nat Microbiol. 2019 Dec;4(12):2319–2330. https://doi.org/10.1038/s41564-019-0541-3

19. Chew SS, Lubowski DZ. Clostridium septicum and malignancy. ANZ J Surg. 2001 Nov;71(11):647–649. https://doi.org/10.1046/j.1445-1433.2001.02231.x

20. Hammond SP, Buckley MW, Petruzziello G, Koo S, Marty FM, Baden LR. Clinical characteristics and outcomes of clostridial bacteraemia in cancer patients. Clinical Microbiology and Infection. 2014 Aug 1;20(8):752–757. https://doi.org/10.1111/1469-0691.12462